%0 Journal Article
%T Pilot study of bevacizumab in combination with docetaxel and
cyclophosphamide as adjuvant treatment for patients with early stage HER-2
negative breast cancer, including analysis of candidate circulating markers of
cardiac toxicity: ICORG 08¨C10 trial
%A Alex J. Eustace
%A Alexandra Canonici
%A Alice C. O¡¯Farrell
%A Andres Hernando
%A Annette T. Byrne
%A Ashwini Maratha
%A Bonnie Ky
%A Brian Moulton
%A David W. Murray
%A Denis M. Collins
%A Dimitrios Tryfonopoulos
%A Enda McDermott
%A Giuseppe Gullo
%A Gregory Leonard
%A Imelda Parker
%A Janice Walshe
%A John Crown
%A John McCaffrey
%A Kathleen Scott
%A Liam Grogan
%A Maccon Keane
%A Mairin Rafferty
%A Michael J. Kennedy
%A Michael J. Martin
%A Miriam O¡¯Connor
%A Norma O¡¯Donovan
%A Oscar Breathhnach
%A Patrick Dicker
%A Paul Donnellan
%A Paula M. Calvert
%A Rajnish Gupta
%A Verena Murphy
%A William M. Gallagher
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919864236
%K bevacizumab
%K breast cancer
%K cardiotoxicity biomarker
%K docetaxel/cyclophosphamide
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657121/